OSUR vs. ANIK, CERS, UTMD, ATRI, SKIN, SRDX, PLSE, NVRO, NPCE, and OFIX
Should you be buying OraSure Technologies stock or one of its competitors? The main competitors of OraSure Technologies include Anika Therapeutics (ANIK), Cerus (CERS), Utah Medical Products (UTMD), Atrion (ATRI), Beauty Health (SKIN), Surmodics (SRDX), Pulse Biosciences (PLSE), Nevro (NVRO), NeuroPace (NPCE), and Orthofix Medical (OFIX). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
In the previous week, OraSure Technologies had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for OraSure Technologies and 4 mentions for Anika Therapeutics. OraSure Technologies' average media sentiment score of 0.44 beat Anika Therapeutics' score of 0.17 indicating that Anika Therapeutics is being referred to more favorably in the media.
OraSure Technologies has a net margin of 13.23% compared to OraSure Technologies' net margin of -49.60%. Anika Therapeutics' return on equity of 14.50% beat OraSure Technologies' return on equity.
OraSure Technologies received 248 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 69.86% of users gave OraSure Technologies an outperform vote while only 64.30% of users gave Anika Therapeutics an outperform vote.
OraSure Technologies has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
Anika Therapeutics presently has a consensus price target of $29.50, indicating a potential upside of 13.90%. OraSure Technologies has a consensus price target of $6.38, indicating a potential upside of 15.91%. Given Anika Therapeutics' higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Anika Therapeutics.
91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 5.9% of Anika Therapeutics shares are owned by company insiders. Comparatively, 3.4% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Anika Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.
Summary
OraSure Technologies beats Anika Therapeutics on 12 of the 17 factors compared between the two stocks.
Get OraSure Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OSUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OraSure Technologies Competitors List
Related Companies and Tools
